The current GSK CTR will be replaced on 26th September 2008 by the new GSK Clinical Study Register and you will be directed to a new url.


Welcome to the GlaxoSmithKline Clinical Trial Register

The GlaxoSmithKline (GSK) Clinical Trial Register provides an easily accessible repository of data from GSK-sponsored clinical trials, supplementing communications in journals, at scientific meetings, in letters to healthcare professionals and in approved prescribing information. GSK-sponsored trials are those for which GSK is ultimately responsible for all aspects of the study (e.g., regulatory approvals, site selection, protocol development, initiation, monitoring, safety reporting, and data analysis), even if some or all of these activities are transferred to another party. The Register will not routinely provide data from trials (view Phases of Clinical Trials) that are not sponsored by GSK.
Please Note: By using this site you agree to our Terms and Conditions of use.

It is important to emphasize that approved prescribing information must continue to guide appropriate use of GSK medicines. This information may vary from country to country. Before prescribing any product mentioned in this Register, Healthcare Professionals should consult prescribing information approved in their country (view UK and US information for Healthcare Professionals ). For prescribing information on individual products in countries outside the UK and US, please refer to the local GSK organisation in those countries (view GSK Contact information).

If further information is required on medicines in this Register, it should be noted that regulations sometimes restrict information which GSK can disclose directly to the public. The intention of this Register is to provide scientific information obtained from studies of GSK medicines. For healthcare advice, members of the public should consult Healthcare Professionals.

The Register provides scientific, non-promotional summaries of clinical trials in a consistent format, irrespective of whether the results may be viewed as positive or negative for GSK medicines.

A summary of a clinical trial involving patients typically includes:

  1. Study title/rationale/objectives/phase.
  2. Study design/treatment schedule/location(s).
  3. Statistical methods.
  4. Study period.
  5. Study population/demographics (view further information).
  6. Results for primary and secondary endpoints defined in the trial protocol (view further information).
  7. Adverse events.
  8. References to publications in the medical literature, when publications of individual studies exist. When it has not been possible to publish a clinical trial within one year of posting on the Register, a conclusion will be added to the trial summary.

Summary results from healthy volunteer studies typically include pharmacokinetic and/or pharmacodynamic information.

The Register will include clinical trials of marketed products completed since the formation of GSK on December 27, 2000. The posting of studies is progressing as the data are entered into the common Register format.

For new GSK medicines and new formulations of marketed medicines, GSK intends to post summaries of pre-marketing trials no later than the first launch of a medicine or new formulation in a major market. For already marketed GSK medicines and formulations, GSK intends to post summaries of trials as they are completed and analyzed, and the summaries are written. GSK plans to include pre-marketing trials of new formulations before launch in a major market when these trials provide important safety information that is relevant to marketed formulations.

In some instances, there may be a delay in posting complete trial summaries because GSK will need to seek intellectual-property protection or to comply with policies of medical journals to which manuscripts have been submitted for publication. Additionally, GSK may be required to withhold certain trial summaries to comply with confidentiality provisions in agreements with other parties.

The Register includes trial summaries that have been written to date, and will grow as additional summaries are completed.